Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

被引：0
|
作者：
Brock, J. E.
Milner, D. A.
Ho, K.
Natalie, W.
Victor, C.
Annaliza, R.
Teresa, B.
Kathryn, G-F
Edwin, L. W.
Jodi, W.
Wendy, W.
Michael, B.
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Cepheid, Sunnyvale, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-05-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-05-07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ER, PR, and HER2 assessment in Hispanic women with breast cancer: A comparison between IHC and AQUA technology.
    Di Marco, Anna Maria
    Ruiz, Jose Alberto
    Moreno, Maryangely
    El Hader, Carlos
    Baez, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Gene and protein expression profiles of HER2, ER, PR, and Ki67 in matched pair samples of primary (PBC) and metastatic breast cancer (MBC) tissues
    Wallwiener, M.
    Deutsch, T. M.
    Hartkopf, A. D.
    Domschke, C.
    Taran, F-A
    Brucker, S.
    Wirtz, R.
    Trumpp, A.
    Schneeweiss, A.
    CANCER RESEARCH, 2016, 76
  • [33] Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist
    Badr, Nahla M.
    Zaakouk, Mohamed
    Zhang, Qi
    Kearns, Daniel
    Kong, Anthony
    Shaaban, Abeer M.
    HISTOPATHOLOGY, 2024, 85 (03) : 437 - 450
  • [34] GeneXpert® breast cancer STRAT4 assay demonstrates high concordance of ESR1, PgR, HER2, and Ki67 with central IHC and FISH testing in FFPE breast tumor tissues
    Wong, E.
    Wu, N.
    Acca, B.
    Dias, H.
    Quigley, N.
    Beqaj, S. S.
    David, K.
    Davenport, S.
    Press, M.
    BREAST, 2017, 32 : S49 - S49
  • [35] Ki67 assessment in ER positive / HER2 negative breast cancer: A comparative study between different scoring methods
    Lashen, A. L.
    Toss, M. T.
    Green, A. G.
    Mongan, N. M.
    Rakha, E. R.
    JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
  • [36] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Discrepancy of labeling index Ki67 in ER positive HER2 negative breast cancer determined by image analysis software and visual assessment
    Kushnarev, V.
    Kudaibergenova, A.
    Artemyeva, A.
    VIRCHOWS ARCHIV, 2017, 471 : S203 - S203
  • [38] Assessment of high Ki67 (≥20%) ER+HER2-breast cancer with a 21-gene multigene assay
    Ahn, S. G.
    Bae, S. J.
    Jang, J. S.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S608 - S608
  • [39] Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
    Hu, Xueyang
    Chen, Wenjun
    Li, Fanfan
    Ren, Pengfei
    Wu, Hongyang
    Zhang, Congjun
    Gu, Kangsheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study
    Poorolajal, Jalal
    Nafissi, Nahid
    Akbari, Mohammad Esmaeil
    Mahjub, Hossein
    Esmailnasab, Nader
    Babaee, Ebrahim
    ARCHIVES OF IRANIAN MEDICINE, 2016, 19 (10) : 680 - 686
12345